Archives

The ZARADEMP project (ZARAgoza DEMentia
DEPression project) was designed as a longitudinal,
community-based study to examine the incidence
of dementia and the risk factors in incident cases of
dementia. It was carried out in Zaragoza, a typical,
large city in Spain, with an important proportion
of inhabitants coming from surrounding rural
areas (12). A stratified random sample of individuals
55 years of age and older, with proportional
allocation by age and sex, drawn from the eligible
individuals (n = 157 787) in the Spanish official
census lists of 1991, was invited to participate in
the baseline examination.

The Atherosclerosis Risk in Communities Study (ARIC) is a prospective epidemiologic study conducted in four U.S. communities. ARIC is designed to investigate the etiology and natural history of atherosclerosis, the etiology of clinical atherosclerotic diseases, and variation in cardiovascular risk factors, medical care and disease by race, gender, location, and date. Since 2011 a large ancillary study, the ARIC Neurocognitive Study (ARIC-NCS) has been assessing neurocognitive status and adjudicating possible cases of dementia.

Four ARIC field centers each randomly selected and recruited a cohort sample of approximately 4,000 individuals aged 45-64 from a defined population in their community. A total of 15,792 participants received an extensive baseline examination (visit 1, 1987-1989), including medical, social, and demographic data collection. Subsequent examinations occurred in 1990-92 (visit 2), 1993-95 (visit 3), 1996-98 (visit 4), 2011-2013 (visit 5) and 2016-2017 (visit 6). Visit 7 (2018-2019) is currently in progress. Follow-up occurs annually (semi-annually since 2012) by telephone to maintain contact with participants and to assess health status of the cohort.

The Cardiovascular Health Study (CHS) is an NHLBI-funded observational study of risk factors for cardiovascular disease in adults 65 years or older. Starting in 1989, and continuing through 1999, participants underwent annual extensive clinical examinations. Measurements included traditional risk factors such as blood pressure and lipids as well as measures of subclinical disease, including echocardiography of the heart, carotid ultrasound, and cranial magnetic-resonance imaging (MRI). At six month intervals between clinic visits, and once clinic visits ended, participants were contacted by phone to ascertain hospitalizations and health status.

Information on dementia comes from two Ancillary Studies. The CHS Cognition Study (Dr. Lewis Kuller, PI) included 3608 participants who had an MRI in 1992-94 and who were followed for dementia through 1999. A follow-up study was done at the Pittsburgh field center that included 532 participants followed through 2013 (Dr. Oscar Lopez,PI).

ULSAM is a unique, ongoing, longitudinal, epidemiologic study based on all available men, born between 1920 and 1924, in Uppsala County, Sweden. The men were investigated at the ages of 50, 60, 70, 77, 82 88 and 93 years. The reinvestigations in ULSAM were based on the previous investigations. Full screening and official registry data is available in our databases and more data is continuously added.

Health examination at 93 years of age was carried out between December 2013 and March 2015. To this examination 245 men have been invited. Totally 147 men (60%) participated in the investigation. Of these, 23 men were examined at the hospital and 102 were visited at home by a nurse. In addition, 22 men completed only a questionnaire. To this examination even spouses were invited. In the complete examination 43 spouses have participated and 11 completed only a questionnaire.

The MemoVie cohort study aims to investigate the living conditions or risk factors under which the normal cognitive capacities of the senior population in Luxembourg (? 65?year-old) evolve (1) to mild cognitive impairment (MCI) ? transitory non-clinical stage ? and (2) to AD. Identifying MCI and AD predictors undeniably constitutes a challenge in public health in that it would allow interventions which could protect or delay the occurrence of cognitive disorders in elderly people. In addition, the MemoVie study sets out to generate hitherto unavailable data, and a comprehensive view of the elderly population in the country.

A 1-year follow-up was included in the original design of the study. The enrolled participants have been followed-up.

A population-based prospective study of cerebro-cardiovascular diseases was begun in 1961 in the town of Hisayama, a suburb of the Fukuoka metropolitan area of Kyushu Island in Japan. In addition, comprehensive surveys of cognitive impairment in the elderly of this town have been conducted since 1985. In 1988, a total of 1,228 residents aged ?60 years (91.1% of the total population in this age group) participated in a screening examination for the present study. After exclusion of 33 subjects who had dementia, 90 who had already had breakfast, 5 who were on insulin therapy, and 81 who could not complete the OGTT, a total of 1,019 subjects without dementia underwent the OGTT. From a total of 1,019 subjects, 2 who died before starting follow-up were excluded, and the remaining 1,017 subjects (437 men and 580 women) were enrolled in this study.

The subjects were followed up prospectively for 15 years, from December 1988 to November 2003 (mean 10.9 years; SD 4.1 years).

In 1999 the Swedish Ministry for Social Affairs promoted and supported a national project aimed at monitoring and evaluating the care-of-the-elderly system in Sweden. To achieve these aims, four longitudinal individual-based data collection describing the aging process and encompassing the care system as whole, has been initiated. This project was named The Swedish National study on Aging and Care (SNAC).

SNAC-K is conducted by the Stockholm Gerontology Research Center in collaboration with Aging Research Center (ARC), Karolinska Institutet.

SNAC-K includes two studies: SNAC-K population study and SNAC-K care system study.

The Kungsholmen Project is a longitudinal population-based study on ageing and dementia, carried out by the Stockholm Gerontology Research Center in collaboration with Aging Research Center (ARC), Karolinska Institutet.

The project, which started in 1987, has gathered a 12-year long database and offers information on aging from a multidisciplinary perspective. All persons that were born before 1913 and lived in the Kungsholmen district of Stockholm, were invited to participate (a total of 2368 persons on October 1st, 1987, including both community-dwelling and institutionalized persons). Later, the research additionally included all 90+ old subjects living in the St. Göran parish, an adjacent geographical area. The baseline phase and four follow-ups have been completed, with the last phase concluding in the summer of 2000. Time 1 was the only measurement occasion when a two-phase study design was adopted, with an extensive clinical examination performed after a screening phase. At every other occasion, all participants were interviewed by nurses, clinically examined by physicians, and assessed by psychologists.

The Uppsala Birth Cohort Multigeneration Study (UBCoS) started in 2005 when we were first able to combine existing data on a representative and well-defined cohort of 14,192 males and females born in Uppsala from 1915-1929 (the Uppsala Birth Cohort: UBCoS) with information on descendants of the original cohort members obtained from routine registers.

In 2007-2011, the study was further developed by additional data collection in school archives and records from Census 1930 and the period of follow-up was extended till end of year 2009.

The study is unique in investigating intergenerational effects as “forward in time” processes, starting at the beginning of the last century (i.e. well before any of the routine registers were in place). Intergenerational associations can be currently investigated in more than 140,000 study subjects from families spanning up to five generations, including the 14,192 original cohort members, their 22,559 children, 38,771 grandchildren and 25,471 great grandchildren born up to 2009.

ASPREE is a double-blind, randomized, placebo-controlled primary prevention trial designed to assess whether daily active treatment of 100 mg enteric-coated aspirin will extend the duration of disability-free life in healthy participants aged 70 years and above except for Hispanic and African American minority groups in the U.S. where the minimum age of entry is 65 years.

The primary objective is to determine whether low-dose aspirin prolongs life, or life free of dementia, or life free of significant, persistent physical disability in the healthy elderly. Secondary objectives relate to the effects of low-dose aspirin on the key outcome areas of death, cardiovascular disease, dementia and cognitive decline, cancer, physical disability, depression and major bleeding episodes. Variables were collected annually through visits and for the purposes of retention telephone calls were scheduled at set points through the 7 years.